
Tonix Pharmaceuticals Holding Corp.: updates and filings
Price
$2.38
November 20, 2026Market cap $46M
What Ploutos Investor adds for Tonix Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 47% since Nov 9, 2026, when the 10-Q these figures come from was filed ($4.49 then, $2.38 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 9, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Other material eventsForm8-K
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 15, 2026Results of operations, other material eventsForm8-K
- Oct 2, 2026Other material eventsForm8-K
- Sep 22, 2026Other material eventsForm8-K
- Sep 8, 2026Other material eventsForm8-K
- Aug 18, 2026Officer or director change, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Aug 3, 2026Regulation FD disclosure, other material eventsForm8-K
- Jul 21, 2026Officer or director changeForm8-K
- Jul 13, 2026Regulation FD disclosure, other material eventsForm8-K
- Jul 1, 2026Shares registered for employeesFormS-8
- Jun 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 8, 2026Regulation FD disclosure, other material eventsForm8-K
- May 27, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 11, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 8-K | Other material events | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 15, 2026 | 8-K | Results of operations, other material events | Document |
| Oct 2, 2026 | 8-K | Other material events | Document |
| Sep 22, 2026 | 8-K | Other material events | Document |
| Sep 8, 2026 | 8-K | Other material events | Document |
| Aug 18, 2026 | 8-K | Officer or director change, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Aug 3, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jul 21, 2026 | 8-K | Officer or director change | Document |
| Jul 13, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jul 1, 2026 | S-8 | Shares registered for employees | Document |
| Jun 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 8, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 9, 2008. Of its note and share prospectuses (424B, FWP), the newest 40 of 67.
The full analysis
What do Tonix Pharmaceuticals's filings show?
The filings are where every one of Tonix Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.